SHENYANG, China and VILLA GUARDIA, Italy, Jan. 25, 2015 /PRNewswire/-- 3SBio Inc., "3SBio", a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that on December 31, 2014, 3SBio acquired the entire share capital of Sirton Pharmaceuticals SpA ("Sirton") from First Shanghai Limited.
"Expanding 3SBio's footprint in key developed markets is a core strategic objective for 3SBio," commented Dr. Jing Lou, Chairman and Chief Executive Office of 3SBio Inc. He continued, "With a team of experienced professionals and a client base of leading pharmaceutical companies, Sirton provides 3SBio with a solid base to manufacture, develop and market pharmaceutical products in Europe. We look forward to working with Sirton's management team and clients to provide safe, affordable and innovative medicines to patients across Europe."
Mr. Giorgio Biella, Managing Director of Sirton, added, "My colleagues and I look forward to working with the team from 3SBio as we pursue our common goal of manufacturing high-quality medicines for international markets." He continued, "3SBio's proven R&D capabilities, global business development strategies, and strong financial position will complement Sirton's existing client relationships and manufacturing experience in Europe."
About Sirton Pharmaceuticals SpA
Sirton Pharmaceuticals SpA ("Sirton") is a pharmaceutical contract manufacturing company located in Villa Guardia, near Cuomo, Italy. Sirton produces injectable pharma products, including pre-filled syringes, liquid vials, freeze-dried vials and ampoules, and pharmaceutical development services including lyophilization process development, analytical method development and validation, stability studies and manufacturing of clinical study materials. Sirton's customers are leading international pharmaceutical companies, including Mylan, Sandoz, Sanofi Avenis France, Crinos and UCB Pharma. Sirton also develops and produces generic pharmaceutical products including zoledronic acid, through Ingenerics S.r.l, a joint venture with Tripharma S.p.A.
For more information visit www.sirton.it.
About 3SBio Inc.
3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Since its founding in 1993, 3SBio's R&D efforts have resulted in four NDAs for biological medicines, including TPIAO, the first rhTPO approved worldwide.
Pipeline candidates include Uricase PEG-20, a modified pegylated recombinant uricase from Candida utilis for the treatment of refractory gout and tumor lysis syndrome which has completed US Phase 1 trials; NuPIAO, a long-acting erythropoiesis-stimulating agent (ESA) for anemia associated with renal failure or chemotherapy and peri-operative blood cell mobilization which has received China FDA's approval to initiate clinical trials; SSS07, an anti-TNF monoclonal antibody for treating rheumatoid arthritis, psoriasis, and potentially other inflammatory diseases; Leukotuximab/SSS19, an anti-CD43/JL-1 monoclonal antibody for treating acute leukemia; and Tanibirumab/SSS23, a anti-VEGFR2 monoclonal antibody for treating solid tumor.
A new state-of-the-art mammalian biological manufacturing facility in Shenyang is the first and only rhEPO facility in China that conforms to both Chinese and European pharmacopeia standards. Planning is underway to develop monoclonal antibody manufacturing capabilities.
3SBio is China's leading specialist in nephrology and oncology supportive care with more than 600 sales professionals covering over 3,000 hospitals in key cities supported by a nationwide network of 120 distributors and logistics providers. EPIAO has been the top selling rhEPO product in China since 2002 with a market share over 40%.
Please visit www.3sbio.com for additional information.
3SBio Contact Information
| Tan Bo |
Jiang Fei, PhD |
Tom Folinsbee |
Donald Wyatt |
| Chief Financial Officer |
Director, Business Development |
Director, Corporate Development |
VP, Business Development & Alliance Management |
| 3SBio Inc. |
3SBio Inc. |
3SBio Inc. |
3SBio Inc. |
| B-13, Grand Place 5 Huizhong Road, Chaoyang District, Beijing, China 100101 |
Shenxin Building 801-802, 200 Ninghai Dong Rd, Huangpu District, Shanghai, China 200021 |
Unit 402 Fairmont House, No.8 Cotton Tree Drive, Admiralty Hong Kong |
No. 3 A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang, China 110027 |
| Tel: +86 10 8489 2211 |
Tel: +86 186 4022 0510 |
Tel: +852 8191 6991 |
US Tel: +1 425 516 7491 |
| Fax: +86 10 8489 2951 |
Fax: +86 21 6374 4922 |
Fax: +852 3007 9376 |
China Tel: +86 138 1816 5538 |
| Email: [email protected] |
Email: [email protected] |
Email: [email protected] |
Email: [email protected] |
Sirton Pharmaceuticals SpA Contact Information
| Giorgio Biella Managing Director Piazza XX Settembre, 2 22079 Villa Guardia Como -- Italy Tel: +39 031 385343 Fax: +39 031 385329 Email: [email protected] |
SOURCE 3SBio Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article